Published in Clin Neurophysiol on March 05, 2011
Cortical Function in Asymptomatic Carriers and Patients With C9orf72 Amyotrophic Lateral Sclerosis. JAMA Neurol (2015) 1.51
Mechanisms, models and biomarkers in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener (2013) 1.16
Transcranial magnetic stimulation and amyotrophic lateral sclerosis: pathophysiological insights. J Neurol Neurosurg Psychiatry (2012) 1.14
Biomarkers in amyotrophic lateral sclerosis: opportunities and limitations. Nat Rev Neurol (2011) 1.07
Advances in motor neurone disease. J R Soc Med (2014) 1.01
Delayed disease onset and extended survival in the SOD1G93A rat model of amyotrophic lateral sclerosis after suppression of mutant SOD1 in the motor cortex. J Neurosci (2014) 0.95
F Wave Study in Amyotrophic Lateral Sclerosis: Assessment of Segmental Motoneuronal Dysfunction. Chin Med J (Engl) (2015) 0.84
Pathophysiological and diagnostic implications of cortical dysfunction in ALS. Nat Rev Neurol (2016) 0.82
Cortical dysfunction underlies the development of the split-hand in amyotrophic lateral sclerosis. PLoS One (2014) 0.80
Eye-tracking in amyotrophic lateral sclerosis: A longitudinal study of saccadic and cognitive tasks. Amyotroph Lateral Scler Frontotemporal Degener (2015) 0.79
Oligodendrocytes contribute to motor neuron death in ALS via SOD1-dependent mechanism. Proc Natl Acad Sci U S A (2016) 0.79
Transcranial Magnetic Stimulation for the Assessment of Neurodegenerative Disease. Neurotherapeutics (2016) 0.79
Why is ALS so excited? Clin Neurophysiol (2011) 0.76
Apical dendrite degeneration, a novel cellular pathology for Betz cells in ALS. Sci Rep (2017) 0.75
Cortical synaptic and dendritic spine abnormalities in a presymptomatic TDP-43 model of amyotrophic lateral sclerosis. Sci Rep (2016) 0.75
New developments and future opportunities in biomarkers for amyotrophic lateral sclerosis. Transl Neurodegener (2015) 0.75
Amyotrophic lateral sclerosis. Lancet (2011) 5.86
Controversies and priorities in amyotrophic lateral sclerosis. Lancet Neurol (2013) 2.52
Guillain-Barré syndrome: an update. J Clin Neurosci (2009) 2.46
Biomarkers in amyotrophic lateral sclerosis. Lancet Neurol (2009) 2.20
Clinical diagnosis and management of amyotrophic lateral sclerosis. Nat Rev Neurol (2011) 2.08
Botulinum toxin modulates cortical maladaptation in post-stroke spasticity. Muscle Nerve (2013) 2.00
Cortical hyperexcitability may precede the onset of familial amyotrophic lateral sclerosis. Brain (2008) 1.94
Isolated bulbar phenotype of amyotrophic lateral sclerosis. Amyotroph Lateral Scler (2011) 1.75
Segmental facial anhidrosis and tonic pupils with preserved deep tendon reflexes: a novel autonomic neuropathy. J Neuroophthalmol (2005) 1.63
Modulatory effects on axonal function after intravenous immunoglobulin therapy in chronic inflammatory demyelinating polyneuropathy. Arch Neurol (2011) 1.55
Cortical excitability testing distinguishes Kennedy's disease from amyotrophic lateral sclerosis. Clin Neurophysiol (2008) 1.54
Split-hand index for the diagnosis of amyotrophic lateral sclerosis. Clin Neurophysiol (2012) 1.52
Oxaliplatin-induced neurotoxicity: changes in axonal excitability precede development of neuropathy. Brain (2009) 1.50
Changes in human sensory axonal excitability induced by an ischaemic insult. Clin Neurophysiol (2008) 1.49
Progressive axonal dysfunction and clinical impairment in amyotrophic lateral sclerosis. Clin Neurophysiol (2012) 1.49
Novel threshold tracking techniques suggest that cortical hyperexcitability is an early feature of motor neuron disease. Brain (2006) 1.47
Corticomotoneuronal function in asymptomatic SOD-1 mutation carriers. Clin Neurophysiol (2010) 1.47
FUS mutations in amyotrophic lateral sclerosis: clinical, pathological, neurophysiological and genetic analysis. J Neurol Neurosurg Psychiatry (2009) 1.44
Riluzole: a glimmer of hope in the treatment of motor neurone disease. Med J Aust (2005) 1.42
Regional differences in ulnar nerve excitability may predispose to the development of entrapment neuropathy. Clin Neurophysiol (2010) 1.41
Scurvy and stroke - is there an association? Med J Aust (2010) 1.40
Axonal loss and myelin in early ON loss in postacute optic neuritis. Ann Neurol (2008) 1.39
Oxaliplatin-induced neurotoxicity and the development of neuropathy. Muscle Nerve (2005) 1.37
Acute abnormalities of sensory nerve function associated with oxaliplatin-induced neurotoxicity. J Clin Oncol (2009) 1.37
Chemotherapy-induced peripheral neurotoxicity: a critical analysis. CA Cancer J Clin (2014) 1.36
Neurotoxic marine poisoning. Lancet Neurol (2005) 1.33
Motor neuron dysfunction in frontotemporal dementia. Brain (2011) 1.31
Uremic neuropathy: clinical features and new pathophysiological insights. Muscle Nerve (2007) 1.30
Axonal ion channels from bench to bedside: a translational neuroscience perspective. Prog Neurobiol (2009) 1.27
Long-term neuropathy after oxaliplatin treatment: challenging the dictum of reversibility. Oncologist (2011) 1.22
Axonal excitability properties in amyotrophic lateral sclerosis. Clin Neurophysiol (2006) 1.22
Pathophysiology of neurodegeneration in familial amyotrophic lateral sclerosis. Curr Mol Med (2009) 1.19
Does interneuronal dysfunction contribute to neurodegeneration in amyotrophic lateral sclerosis? Amyotroph Lateral Scler (2012) 1.18
Fatigue in multiple sclerosis: mechanisms and management. Clin Neurophysiol (2010) 1.18
Altered nerve excitability properties in established diabetic neuropathy. Brain (2005) 1.17
Assessment of cortical excitability using threshold tracking techniques. Muscle Nerve (2006) 1.17
Grey and white matter changes across the amyotrophic lateral sclerosis-frontotemporal dementia continuum. PLoS One (2012) 1.15
Transcranial magnetic stimulation and amyotrophic lateral sclerosis: pathophysiological insights. J Neurol Neurosurg Psychiatry (2012) 1.14
Activity-dependent excitability changes suggest Na+/K+ pump dysfunction in diabetic neuropathy. Brain (2008) 1.10
FOSMN syndrome: novel insight into disease pathophysiology. Neurology (2012) 1.10
How common are behavioural changes in amyotrophic lateral sclerosis? Amyotroph Lateral Scler (2010) 1.09
Amyotrophic lateral sclerosis and frontotemporal dementia: A behavioural and cognitive continuum. Amyotroph Lateral Scler (2012) 1.08
Abnormalities in cortical and peripheral excitability in flail arm variant amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry (2007) 1.05
Changes in human sensory axonal excitability induced by focal nerve compression. J Physiol (2010) 1.04
Transsynaptic retinal degeneration in optic neuropathies: optical coherence tomography study. Invest Ophthalmol Vis Sci (2012) 1.03
Altered motor nerve excitability in end-stage kidney disease. Brain (2005) 1.02
Nerve function and dysfunction in acute intermittent porphyria. Brain (2008) 1.00
Oxaliplatin and axonal Na+ channel function in vivo. Clin Cancer Res (2006) 1.00
Engaging in patient decision-making in multidisciplinary care for amyotrophic lateral sclerosis: the views of health professionals. Patient Prefer Adherence (2012) 1.00
Fatigue and activity dependent changes in axonal excitability in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry (2007) 0.98
Impact of oxaliplatin-induced neuropathy: a patient perspective. Support Care Cancer (2012) 0.98
Treatment of proximal upper limb tremor with botulinum toxin therapy. Mov Disord (2013) 0.97
INSPIRATIonAL--INSPIRAtory muscle training in amyotrophic lateral sclerosis. Amyotroph Lateral Scler (2009) 0.96
Interrelationship of optical coherence tomography and multifocal visual-evoked potentials after optic neuritis. Invest Ophthalmol Vis Sci (2009) 0.96
Upregulation of persistent sodium conductances in familial ALS. J Neurol Neurosurg Psychiatry (2009) 0.95
Corticomotoneuronal function and hyperexcitability in acquired neuromyotonia. Brain (2010) 0.95
Quantifying disease progression in amyotrophic lateral sclerosis. Ann Neurol (2014) 0.94
Threshold behaviour of human axons explored using subthreshold perturbations to membrane potential. J Physiol (2008) 0.94
Axonal changes in spinal cord injured patients distal to the site of injury. Brain (2007) 0.94
Neurological complications of chronic kidney disease. Nat Rev Neurol (2009) 0.93
Has potassium been prematurely discarded as a contributing factor to the development of uraemic neuropathy? Nephrol Dial Transplant (2004) 0.93
Riluzole exerts central and peripheral modulating effects in amyotrophic lateral sclerosis. Brain (2013) 0.92
Dose effects of oxaliplatin on persistent and transient Na+ conductances and the development of neurotoxicity. PLoS One (2011) 0.92
Pathophysiological insights into ALS with C9ORF72 expansions. J Neurol Neurosurg Psychiatry (2013) 0.92
Neurophysiological index as a biomarker for ALS progression: validity of mixed effects models. Amyotroph Lateral Scler (2011) 0.91
Assessment of disease progression in motor neuron disease. Lancet Neurol (2005) 0.91
Assessing the accuracy of a combination of clinical tests for identifying carpal tunnel syndrome. J Clin Neurosci (2009) 0.90
Congenital myasthenic syndromes. J Clin Neurosci (2008) 0.90
Cortical atrophy in ALS is critically associated with neuropsychiatric and cognitive changes. Neurology (2013) 0.90
Pathophysiological insights derived by natural history and motor function of spinal muscular atrophy. J Pediatr (2012) 0.89
Remyelination of optic nerve lesions: spatial and temporal factors. Mult Scler (2010) 0.89
The case of a 48 year-old woman with bizarre and complex delusions. Nat Rev Neurol (2010) 0.89
Axonal loss in non-optic neuritis eyes of patients with multiple sclerosis linked to delayed visual evoked potential. Neurology (2012) 0.88
Early, progressive, and sustained dysfunction of sensory axons underlies paclitaxel-induced neuropathy. Muscle Nerve (2010) 0.88
Assessment of nerve excitability in toxic and metabolic neuropathies. J Peripher Nerv Syst (2008) 0.88
Puffer fish poisoning: a potentially life-threatening condition. Med J Aust (2002) 0.88
The effects of alterations in conditioning stimulus intensity on short interval intracortical inhibition. Brain Res (2009) 0.87
Predicting a positive response to intravenous immunoglobulin in isolated lower motor neuron syndromes. PLoS One (2011) 0.87
Riluzole therapy for motor neurone disease: an early Australian experience (1996-2002). J Clin Neurosci (2006) 0.87
The puzzling case of hyperexcitability in amyotrophic lateral sclerosis. J Clin Neurol (2013) 0.86
Defining the mechanisms that underlie cortical hyperexcitability in amyotrophic lateral sclerosis. Exp Neurol (2009) 0.86
Inner nuclear layer thickening is inversley proportional to retinal ganglion cell loss in optic neuritis. PLoS One (2013) 0.86
The Genetics of Spinal Muscular Atrophy: Progress and Challenges. Neurotherapeutics (2015) 0.86
Neuropsychiatric changes precede classic motor symptoms in ALS and do not affect survival. Neurology (2013) 0.85
Wernicke's encephalopathy presenting with upbeating nystagmus. J Clin Neurosci (2002) 0.85
Dexpramipexole, the R(+) enantiomer of pramipexole, for the potential treatment of amyotrophic lateral sclerosis. IDrugs (2010) 0.85
Patterns of clinical and electrodiagnostic abnormalities in early amyotrophic lateral sclerosis. Muscle Nerve (2014) 0.85
The relationship between cortical and spinal hyperexcitability and clinical disease severity in stiff-man syndrome. Parkinsonism Relat Disord (2012) 0.85
Effects of hemodiafiltration and high flux hemodialysis on nerve excitability in end-stage kidney disease. PLoS One (2013) 0.85
Cortical dysfunction underlies disability in multiple sclerosis. Mult Scler (2011) 0.84
The utility of multimodal evoked potentials in multiple sclerosis prognostication. J Clin Neurosci (2013) 0.84
Dysfunction of axonal membrane conductances in adolescents and young adults with spinal muscular atrophy. Brain (2011) 0.84